Veterinary Medicines

ALPHA JECT 3000 Emulsion for injection for Atlantic salmon

Authorised
  • Aeromonas salmonicida, strain AL2017, Inactivated
  • Vibrio anguillarum, serotype O1, strain AL 112, Inactivated
  • Vibrio anguillarum, serotype O2a, strain AL 104, Inactivated
Download as PDF

Product identification

Medicine name:
ALPHA JECT 3000 injeksjonsvæske, emulsjon til atlantisk laks
ALPHA JECT 3000 Emulsion for injection for Atlantic salmon
Active substance:
  • Aeromonas salmonicida, strain AL2017, Inactivated
  • Vibrio anguillarum, serotype O1, strain AL 112, Inactivated
  • Vibrio anguillarum, serotype O2a, strain AL 104, Inactivated
Target species:
  • Atlantic salmon
Route of administration:
  • Intraperitoneal use

Product details

Active substance and strength:
  • Aeromonas salmonicida, strain AL2017, Inactivated
    70.00
    Relative Percentage Survival
    /
    1.00
    Dose
  • Vibrio anguillarum, serotype O1, strain AL 112, Inactivated
    75.00
    Relative Percentage Survival
    /
    1.00
    Dose
  • Vibrio anguillarum, serotype O2a, strain AL 104, Inactivated
    75.00
    Relative Percentage Survival
    /
    1.00
    Dose
Pharmaceutical form:
  • Emulsion for injection
Withdrawal period by route of administration:
  • Intraperitoneal use
    • Atlantic salmon
      • Meat and offal
        0
        degree day
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI10AB02
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Norway
Available in:
  • Norway
Package description:
  • UVO injection bags made of a multilayer plastic foil with ethylene vinyl acetate as the product contact layer. Thegiving port is closed with a bromobutyl based rubber stopper.Pack size: 500 ml

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Full application (Article 12(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Pharmaq AS
Marketing authorisation date:
Manufacturing sites for batch release:
  • Pharmaq AS
Responsible authority:
  • Norwegian Medical Products Agency
Authorisation number:
  • 07-5472
Date of authorisation status change:
Reference member state:
  • Ireland
Procedure number:
  • IE/V/0219/001
Concerned member states:
  • Denmark
  • Finland
  • Iceland
  • Norway

Documents

Summary of Product Characteristics

English (PDF)
Published on: 4/05/2025
Download
Norwegian (PDF)
Published on: 16/05/2025
Download

Combined File of all Documents

English (PDF)
Published on: 4/05/2025
Download

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.
Norwegian (PDF)
Published on: 16/05/2025
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."